Having previously focused on offshore IPOs, China managers with US dollar funds are now considering the Star Market. But going onshore means more regulation as well as high valuations
Ucommune, a Chinese co-working space operator that failed to get traction with an attempted New York IPO last year, has been acquired by a US-listed special purpose acquisition company (SPAC) at a valuation of $764.9 million.
TA Associates has invested an undisclosed sum in the National Stock Exchange of India (NSE).
Chinese radiotherapy business Hygeia Healthcare, which counts Warburg Pincus, Boyu Capital, and CITIC Capital among its investors, raised HK$2.22 billion ($286.4 million) in its Hong Kong IPO.
There has been a steady stream of China healthcare IPOs - most of them drug developers - on the domestic, Hong Kong and US bourses in recent months. They might be benefiting from a COVID-19 tailwind but it won't be permanent
Seafolly, an Australian swimwear and beachwear brand owned by L Catterton Asia, has entered administration, citing the “crippling financial impact” of the COVID-19 pandemic.
Agora.io, a real-time voice and video communication platform established by Tony Zhao, formerly CTO of Chinese social networking player YY.com, saw its stock gain 151% on its NASDAQ trading debut following a $350 million IPO.
Tencent Holdings has agreed to acquire the assets of Malaysia-headquartered streaming platform Iflix, which was previously backed by a number of private equity and strategic players.
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
Southern Capital Group and HPEF Capital Partners – formerly Headland Capital Partners – have agreed to sell Singapore-based Canadian International School (CIS) to Hong Kong-listed China Maple Leaf Educational Systems for S$680 million ($488 million),...
Toshiba is exploring ways to fully exit its 40.2% stake in Kioxa Holdings, two years after selling control of the Japanese flash memory division to a Bain Capital-led consortium for an enterprise valuation of JPY2 trillion ($18.7 billion).
Will Chinese companies listed in the US become the latest casualties of tensions between the two countries? It could lead to a narrowing in IPO exit options for PE and VC investors
Genetron Holdings, a Chinese company that uses DNA sequencing to support the diagnosis and treatment of cancer, traded flat on its NASDAQ debut following a larger-than-planned $256 million IPO.
BlueCity Holdings, the company behind Chinese gay dating platform Blued, has filed an application to list on NASDAQ, which would provide a liquidity event for several PE and VC investors.
Ascendent Capital Partners has agreed to make a full exit from Chinese dairy producer Ningxia Harmony Dairy Development with New Hope Dairy set to buy the business for an enterprise valuation of RMB1.7 billion ($240 million).
Indian IT outsourcing company Happiest Minds Technologies, which is backed by J.P. Morgan Asset Management, has filed for an initial public offering.
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, rose 49% on its trading debut following a $222.8 million US IPO.
Dada Nexus, a Chinese last-mile delivery platform backed by the likes of JD.com, Walmart, Sequoia Capital China, and DST Global, traded flat on its NASDAQ debut following a $320 million IPO.
DoubleDown Interactive, a STIC Investments-backed Korean online game publisher best known for its flagship casino offering, has filed to list in the US.
Pop Mart International Group, China’s largest fashion toy retailer, has filed for a Hong Kong IPO. Sequoia Capital China, Loyal Valley Capital and Huaxing Growth Fund are its three largest institutional backers.
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, has filed for an IPO in the US.
Advantage Partners has completed its exit from Japanese kitchenware products manufacturer FMI Corporation to Toho Group, a Tokyo-listed food wholesaler that bought a majority stake in the business two years ago.
Kintor Pharmaceutical, a Chinese drug developer backed by the likes of HighLight Capital and Shenzhen Green Pine Capital Partners, posted a 7% gain on debut following a HK$1.86 billion ($240 million) Hong Kong IPO.
The Hong Kong Stock Exchange has tightened disclosure requirements for companies looking to take advantage of two-year-old reforms permitting listings by pre-revenue biotech companies.